US Edition
Eli Lilly's Oral GLP-1 Pill Matches Injectables, Eyes Approval by Year-End
- Eli Lilly announced today at the American Diabetes Association meeting that its daily pill orforglipron showed effective weight loss and blood sugar reduction in a Phase 3 trial involving type 2 diabetes patients.
- The trial tested three doses over 40 weeks in 559 patients and aimed to confirm orforglipron's efficacy comparable to injectable GLP-1 drugs like Ozempic and tirzepatide.
- The highest dose led to nearly 8% weight loss and blood sugar levels dropped 1.3% to 1.6%, with gastrointestinal side effects similar to other GLP-1 medications including diarrhea and vomiting.
- Ken Custer, Lilly's president of cardiometabolic health, emphasized that orforglipron's oral administration and easier storage could help expand access to weight-loss treatments worldwide.
- Lilly intends to submit regulatory filings for orforglipron as a weight management treatment by the end of 2025 and aims to do the same for its use in diabetes care in 2026, while continuing studies to assess its impact on individuals without diabetes.
68 Articles
68 Articles
Novo Nordisk's arch-rival Eli Lilly is so confident in its upcoming weight loss pill that the company has begun building up a stockpile to supply the entire world ahead of crucial trial results. In a...
Farm Talk Newspaper
New Formulations of GLP-1s Demonstrate Positive Results, Potentially Offering Additional Options for Obesity Medications
Data reveals potential for once-daily oral and monthly injectable treatment alternatives for patients with type 2 diabetes and obesity
Lilly's Oral GLP-1 Orforglipron Demonstrates Efficacy In Type 2 Diabetes Treatment In Phase 3 Trial
(RTTNews) - Eli Lilly And Co.'s (LLY) investigational oral GLP-1 receptor agonist, orforglipron, demonstrated compelling efficacy and a safety profile aligned with that of injectable GLP-1 therapies, according to full Phase 3 results published in The New England Journal of Medici
A new oral anti-diabetes pill, orforglipron, shows similar effectiveness to injectable GLP-1 drugs in a Phase 3 trial.
New Eli Lilly trial suggests weight-loss pill is as strong as Ozempic
The latest clinical trial for Eli Lilly’s weight-loss pill suggests it’s as strong as Ozempic — with no needles required. In an exclusive interview, Dan Skovronsky, the company’s chief scientific officer, says the pills are easier to manufacture, indicating more people should have access to it. NBC’s Stephanie Gosk reports for TODAY on the newest details.
Coverage Details
Bias Distribution
- 65% of the sources are Center
To view factuality data please Upgrade to Premium
